跳至主要内容
临床试验/NCT02753712
NCT02753712已完成3 期

A Two-arm, Randomised, Assessor-blind, Parallel Group Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) and Relvar® Ellipta® DPI on Ventilation Heterogeneity in Subjects With Partially Controlled or Uncontrolled Asthma

Mundipharma Research Limited16 个研究点 分布在 5 个国家目标入组 105 人开始时间: 2016年6月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
105
试验地点
16
主要终点
Measuring peripheral airway resistance (R5-R20)

研究概览

简要总结

The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

fluticasone/vilanterol DPI (Relvar Ellipta DPI)

Active Comparator

Inhalation powder. 92/22µg, I inhalation od

干预措施: Fluticasone/Vilanterol DPI (Relvar Ellipta DPI) (Drug)

Fluticasone/formoterol BAI

Experimental

Pressurised suspension for inhalation 125/5µg, 2 inhalations bid

干预措施: Fluticasone/Formoterol BAI (Drug)

结局指标

主要结局

Measuring peripheral airway resistance (R5-R20)

时间窗: From baseline to week 8

Measuring peripheral airway resistance (R5-R20)

次要结局

  • Measuring distal airway volume and resistance (using impulse oscillometry)(From baseline to week 8 and 9)
  • Evaluate asthma control (using ACQ-6) )(From baseline to week 4 and 8)
  • Evaluate health status (using AQLQ)(From baseline to week 4 and 8)
  • measure ventilation heterogeneity (using Functional Respiratory Imaging)(From baseline to week 9)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

A Study to Evaluate the Effect of... | 临床试验